Aortic StenosisRemote-ASNCT07690748
Remote Monitoring for Patients With Aortic Stenosis
An observational study of Aortic Stenosis, run by Baker Heart and Diabetes Institute.
Trial summary
Remote-AS aims to develop a remote digital monitoring cohort of people with AS and use these data to establish a digital twin intervention to personalise risks and benefits, and optimise the time of surgical or transcatheter aortic valve replacement (AVR) referral. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Aortic Stenosis
- How many people
- 160 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to Aug 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Potential participants will be identified by their cardiologist or cardiothoracic surgeon at high-volume Australian centres in Melbourne.
Who may be able to join
- Male or female ≥18 years of age
- Suitable to undergo MRI scans
- With asymptomatic moderate to severe native AS (based on guideline-recommended diagnosis and care)
- Eligible for Medicare
- Ability and willingness to provide written and informed consent and to comply with the requirements of the study.
Who cannot join
- Serious comorbidity other than AS that limits the life expectancy (<2 years), or affects study participation or outcome (severe frailty and mobility issues [Rockwood frailty score >6], severe kidney disease eGFR<30, infiltrative cardiomyopathy)
- Known heart failure or reduced left ventricular ejection fraction (<50%)
- Moderate or above valvular pathology other than AS
- Contra-indications to CMR (including presence of foreign metallic bodies)
- Known hypersensitivity to adenosine (ever requiring hospital admission with asthma or chronic obstructive pulmonary disease) or gadolinium
- Significant renal impairment (eGFR<30ml/min/m2)
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Remote Monitoring for Asymptomatic Patients With Moderate to Severe Aortic Valve Stenosis - Remote-AS
Remote-AS aims to develop a remote digital monitoring cohort of people with AS and use these data to establish a digital twin intervention to personalise risks and benefits, and optimise the time of surgical or transcatheter aortic valve replacement (AVR) referral. Our digital solution will also seek modelling for optimal care for patients to whom AVR is indicated who choose not to undergo the procedure, supporting a patient-selected observational strategy for managing heart failure symptoms, facilitating patient education and self-care.
Objectives of the study are:
Read more
- To establish a large-scale interdisciplinary research program to drive implementation of substantial improvements to health care and/or health system effectiveness in patients with aortic stenosis (AS)
- To establish a new model of patient-centred management strategy for asymptomatic severe AS to inform the optimal time at which valve intervention should take place
- For patients to whom AVR is indicated who choose not to undergo the procedure, to support a patient-selected observational strategy for managing heart failure symptoms
- To develop a digital twin with predictive capabilities of artificial intelligence (AI) for guiding the optimal timing of AVR in patients with asymptomatic severe AS
Participants will be patients with asymptomatic moderate to severe native AS (n=160) (based on guideline-recommended diagnosis and care with peak aortic velocity >3.5m/sec).
Participants will undergo:
Wearables: collection of physiological (e.g., blood pressure, heart rate, rhythm) and behavioural (physical activity) data through a wearable device ('smart watch'), collected through the comprehensive remote heart health monitoring and automated feedback delivery system app SMART.
Patient reported outcome measures: KCCQ-CSS; EQ-5D-5L index score; "Toronto Aortic Stenosis" quality of life questionnaires.
Advanced cardiovascular imaging: Cardiovascular magnetic resonance (CMR) imaging; 31phosphorus magnetic resonance spectroscopy (31P-MRS); proton magnetic resonance spectroscopy (1H-MRS); echocardiography.
Comprehensive plasma proteome profiling: Plasma proteomic preparation coupled with the Orbitrap Astral mass spectrometer.
Recording of clinical outcomes.
- Conditions
- Aortic Stenosis
- Medical subject headings
- Aortic Valve Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Aortic stenosis | Patients with asymptomatic moderate to severe native AS (n=160) (based on guideline-recommended diagnosis and care with peak aortic velocity >3.5m/sec). |
What is being measured
The primary outcome is the main question the study is designed to answer.
LV hypertrophy
Left ventricular mass index[g/m2], imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Diastolic function - Mitral inflow E/A ratio
Mitral inflow E/A ratio, imaging endpoint on echocardiography
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Diastolic function - average E/e' ratio
Average E/e' ratio, imaging endpoint on echocardiography
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Diastolic function - septal e' velocity
Septal e' velocity, imaging endpoint on echocardiography.
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Diastolic function - lateral e' velocity
Lateral e' velocity, imaging endpoint on echocardiography.
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Diastolic function - left atrial volume index
Left atrial volume index, imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Diastolic function - peak diastolic strain rate
Peak diastolic strain rate, imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Global longitudinal strain (GLS)
Imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Myocardial perfusion
Rest and adenosine stress CMR-measured myocardial blood flow and myocardial perfusion reserve imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Myocardial energetics index
31P-MRS-measured phosphocreatine to ATP ratio, imaging endpoint on cardiovascular magnetic resonance spectroscopy (MRS)
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Myocardial triglyceride content
Imaging endpoint as measured by 1H-MRS
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Myocardial fibrosis index - extra cellular volume [ECV] fraction
Extra cellular volume [ECV] fraction, tissue characteristic imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Myocardial fibrosis index - index-ECV
Index-ECV, imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Myocardial fibrosis index - scar percentage
Late gadolinium enhancement imaging-assessed scar percentage, imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Secondary outcomes (11)
Physical activity
Digital endpoint measured from wearable devices and processed via the SMART architecture
Measured: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
Blood pressure
Digital endpoint measured from wearable devices and processed via the SMART architecture
Measured: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
Heart rhythm
Digital endpoint measured from wearable devices and processed via the SMART architecture
Measured: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
Heart rate variability
Digital endpoint measured from wearable devices and processed via the SMART architecture
Measured: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
Oxygen saturation
Digital endpoint measured from wearable devices and processed via the SMART architecture
Measured: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
NTproBNP
Blood biomarker
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
High sensitivity cardiac troponin (hscTNT)
Blood biomarker
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Proteomics
Advanced, label-free quantitative mass spectrometry-based proteomics blood biomarkers
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Quality-of-Life questionnaire: KCCQ-CSS
Patient-reported outcome measure via Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score [KCCQ-CSS]
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Quality-of-Life questionnaire: EQ-5D-5L
Patient-reported outcome measure via EuroQoL 5-dimension 5-level [EQ-5D-5L] index score
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Quality-of-Life questionnaire: Toronto AS QoL
Patient-reported outcome measure via "Toronto Aortic Stenosis" quality of life questionnaire
Measured: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2026
- Study start1 Sep 2026 (estimated)
- Primary completionAug 2030 (estimated)
- Study completionAug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aortic StenosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Baker Heart and Diabetes Institute
- Sponsor type
- University, hospital or other
- Collaborators
- The Alfred, Monash Medical Centre, St Vincent's Hospital Melbourne, University of Melbourne, Deakin University, La Trobe University, The University of Western Australia, Melbourne Health
- Responsible party
- Principal investigator, Eylem Levelt, Baker Heart and Diabetes Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07690748
- Sponsor's protocol ID
- 587-25
- Other IDs
- 119917
- Acronym
- Remote-AS
- Status last verified
- Jul 2026
- First submitted
- 22 Mar 2026
- Last updated
- 8 Jul 2026
- Results posted
- No
- Individual data sharing
- Yes: Upon publications, the investigators envisage allowing access to the data in a systematic manner through a platform dedicated to sharing scientific research data (e.g., ShareFile). Specific datasets will be made available after publications by us and sharing of data is intended to be determined on a case-by-case basis at the discretion of the Principal Investigator, and provided agreement to preserve the confidentiality of the information. All data will be shared in a non-identifiable format. Data will be collected, stored and shared in accordance with National Statement 3.1.44 and 3.1.55. If journals request that the research team make raw data available, the anonymised raw non-identifiable data will be shared in a systematic manner through a platform dedicated to sharing scientific research data (e.g., ShareFile). The participant information/consent form includes this information for participants following guidelines from the Australian Research Data Commons (ARDC) guide.
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Remote Monitoring for Asymptomatic Patients With Moderate to Severe Aortic Valve Stenosis - Remote-AS
- ClinicalTrials.gov ID
- NCT07690748
- Acronym / sponsor ID
- Remote-AS / 587-25
- Conditions
- Aortic Stenosis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 160 participants (estimated)
- Lead sponsor
- Baker Heart and Diabetes InstituteUniversity, hospital or other
- Collaborators
- The Alfred, Monash Medical Centre, St Vincent's Hospital Melbourne, University of Melbourne, Deakin University, La Trobe University, The University of Western Australia, Melbourne Health
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- Aug 2030 (estimated)
- Study completion
- Aug 2030 (estimated)
- First posted
- 8 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Remote-AS aims to develop a remote digital monitoring cohort of people with AS and use these data to establish a digital twin intervention to personalise risks and benefits, and optimise the time of surgical or transcatheter aortic valve replacement (AVR) referral. Our digital solution will also seek modelling for optimal care for patients to whom AVR is indicated who choose not to undergo the procedure, supporting a patient-selected observational strategy for managing heart failure symptoms, facilitating patient education and self-care.
Objectives of the study are:
- To establish a large-scale interdisciplinary research program to drive implementation of substantial improvements to health care and/or health system effectiveness in patients with aortic stenosis (AS)
- To establish a new model of patient-centred management strategy for asymptomatic severe AS to inform the optimal time at which valve intervention should take place
- For patients to whom AVR is indicated who choose not to undergo the procedure, to support a patient-selected observational strategy for managing heart failure symptoms
- To develop a digital twin with predictive capabilities of artificial intelligence (AI) for guiding the optimal timing of AVR in patients with asymptomatic severe AS
Participants will be patients with asymptomatic moderate to severe native AS (n=160) (based on guideline-recommended diagnosis and care with peak aortic velocity >3.5m/sec).
Participants will undergo:
Wearables: collection of physiological (e.g., blood pressure, heart rate, rhythm) and behavioural (physical activity) data through a wearable device ('smart watch'), collected through the comprehensive remote heart health monitoring and automated feedback delivery system app SMART.
Patient reported outcome measures: KCCQ-CSS; EQ-5D-5L index score; "Toronto Aortic Stenosis" quality of life questionnaires.
Advanced cardiovascular imaging: Cardiovascular magnetic resonance (CMR) imaging; 31phosphorus magnetic resonance spectroscopy (31P-MRS); proton magnetic resonance spectroscopy (1H-MRS); echocardiography.
Comprehensive plasma proteome profiling: Plasma proteomic preparation coupled with the Orbitrap Astral mass spectrometer.
Recording of clinical outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Aortic stenosis | – | –Patients with asymptomatic moderate to severe native AS (n=160) (based on guideline-recommended diagnosis and care with peak aortic velocity >3.5m/sec). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Potential participants will be identified by their cardiologist or cardiothoracic surgeon at high-volume Australian centres in Melbourne.
Key inclusion criteria (5 listed)
- Male or female ≥18 years of age
- Suitable to undergo MRI scans
- With asymptomatic moderate to severe native AS (based on guideline-recommended diagnosis and care)
- Eligible for Medicare
- Ability and willingness to provide written and informed consent and to comply with the requirements of the study.
Key exclusion criteria (6 listed)
- Serious comorbidity other than AS that limits the life expectancy (<2 years), or affects study participation or outcome (severe frailty and mobility issues [Rockwood frailty score >6], severe kidney disease eGFR<30, infiltrative cardiomyopathy)
- Known heart failure or reduced left ventricular ejection fraction (<50%)
- Moderate or above valvular pathology other than AS
- Contra-indications to CMR (including presence of foreign metallic bodies)
- Known hypersensitivity to adenosine (ever requiring hospital admission with asthma or chronic obstructive pulmonary disease) or gadolinium
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
LV hypertrophy
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Left ventricular mass index[g/m2], imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Diastolic function - Mitral inflow E/A ratio
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Mitral inflow E/A ratio, imaging endpoint on echocardiography
Diastolic function - average E/e' ratio
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Average E/e' ratio, imaging endpoint on echocardiography
Diastolic function - septal e' velocity
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Septal e' velocity, imaging endpoint on echocardiography.
Diastolic function - lateral e' velocity
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Lateral e' velocity, imaging endpoint on echocardiography.
Diastolic function - left atrial volume index
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Left atrial volume index, imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Diastolic function - peak diastolic strain rate
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Peak diastolic strain rate, imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Global longitudinal strain (GLS)
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Myocardial perfusion
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Rest and adenosine stress CMR-measured myocardial blood flow and myocardial perfusion reserve imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Myocardial energetics index
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
31P-MRS-measured phosphocreatine to ATP ratio, imaging endpoint on cardiovascular magnetic resonance spectroscopy (MRS)
Myocardial triglyceride content
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Imaging endpoint as measured by 1H-MRS
Myocardial fibrosis index - extra cellular volume [ECV] fraction
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Extra cellular volume [ECV] fraction, tissue characteristic imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Myocardial fibrosis index - index-ECV
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Index-ECV, imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
Myocardial fibrosis index - scar percentage
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Late gadolinium enhancement imaging-assessed scar percentage, imaging endpoint on cardiovascular magnetic resonance imaging (CMR)
11 secondary outcomes
Physical activity
Time frame: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
Blood pressure
Time frame: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
Heart rhythm
Time frame: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
Heart rate variability
Time frame: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
Oxygen saturation
Time frame: Daily for the duration of the participant's participation in the study (six months post guideline-indicated AVR, or if AVR is not performed until completion of the overall study, i.e. maximum 4 years, whichever comes first).
NTproBNP
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
High sensitivity cardiac troponin (hscTNT)
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Proteomics
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Quality-of-Life questionnaire: KCCQ-CSS
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Quality-of-Life questionnaire: EQ-5D-5L
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Quality-of-Life questionnaire: Toronto AS QoL
Time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Individual participant dataSharing planned: Yes. Upon publications, the investigators envisage allowing access to the data in a systematic manner through a platform dedicated to sharing scientific research data (e.g., ShareFile). Specific datasets will be made available after publications by us and sharing of data is intended to be determined on a case-by-case basis at the discretion of the Principal Investigator, and provided agreement to preserve the confidentiality of the information. All data will be shared in a non-identifiable format. Data will be collected, stored and shared in accordance with National Statement 3.1.44 and 3.1.55. If journals request that the research team make raw data available, the anonymised raw non-identifiable data will be shared in a systematic manner through a platform dedicated to sharing scientific research data (e.g., ShareFile). The participant information/consent form includes this information for participants following guidelines from the Australian Research Data Commons (ARDC) guide.
Related trials for Aortic Stenosis
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Recruiting
Exercise and Diet Supplements for Older Patients Undergoing TAVI: the IRON-TAVI Trial
Aortic Stenosis Disease, Aortic Stenosis Symptomatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Aortic Stenosis, run by Baker Heart and Diabetes Institute.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sjoerd Levelt, PhD (+61385321874, sjoerd.levelt@baker.edu.au), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
LV hypertrophy (time frame: 6-monthly repeat assessments prior to AVR, with a concluding assessment 6 months after AVR). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.